James William Rogers Sells 23,030 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 23,030 shares of Tempus AI stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $45.97, for a total transaction of $1,058,689.10. Following the sale, the chief financial officer now directly owns 164,750 shares in the company, valued at $7,573,557.50. The trade was a 12.26 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

James William Rogers also recently made the following trade(s):

• On Tuesday, February 18th, James William Rogers sold 31,780 shares of Tempus AI stock. The stock was sold at an average price of $82.33, for a total transaction of $2,616,447.40.
• On Wednesday, February 5th, James William Rogers sold 8,712 shares of Tempus AI stock. The stock was sold at an average price of $67.57, for a total value of $588,669.84.

Tempus AI Stock Up 0.0 %

Shares of NASDAQ:TEM opened at $48.04 on Friday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $91.45. The stock’s fifty day moving average price is $56.07 and its 200-day moving average price is $51.45.

Analyst Ratings Changes

TEM has been the subject of a number of research reports. TD Cowen reiterated a “buy” rating and issued a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Needham & Company LLC increased their price target on shares of Tempus AI from $56.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Piper Sandler dropped their price objective on shares of Tempus AI from $70.00 to $55.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Loop Capital decreased their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. Finally, Wolfe Research lowered shares of Tempus AI from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Tempus AI has a consensus rating of “Moderate Buy” and an average price target of $61.18.

Hedge Funds Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently bought and sold shares of TEM. ARK Investment Management LLC lifted its position in Tempus AI by 132.1% during the fourth quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company’s stock valued at $186,343,000 after purchasing an additional 3,141,487 shares during the period. NEA Management Company LLC lifted its holdings in shares of Tempus AI by 17.8% during the 3rd quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock valued at $304,846,000 after buying an additional 813,169 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Tempus AI by 166.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after buying an additional 2,021,394 shares during the last quarter. Nikko Asset Management Americas Inc. grew its holdings in shares of Tempus AI by 166.0% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after acquiring an additional 2,021,394 shares during the period. Finally, Franklin Resources Inc. increased its position in Tempus AI by 240.5% during the fourth quarter. Franklin Resources Inc. now owns 2,762,173 shares of the company’s stock valued at $93,251,000 after acquiring an additional 1,950,862 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.